On Nov. 27, Novacea, Inc. announced Dr. Edward Schnipper ’70 as its new executive vice president and chief medical officer.
“We are very pleased to bring Ed on board as he provides a very strong background of clinical and operational accomplishments and expertise to Novacea. As we conducted our search, we targeted someone who had the experience and the medical credentials to help us transition to a first-tier oncology company,” said John P. Walker, chairman and chief executive officer of Novacea, a biopharmaceutical company focused on in-licensing, developing and commercializing novel cancer therapies.
Schnipper joins Novacea with more than 18 years of management experience in the clinical development of medicines for the pharmaceutical and biotechnology industries. Prior to his new appointment, Schnipper had served as president and chief executive officer of CellGate, Inc., a privately-held biotechnology company, as vice president of Clinical Development at ALZA Corporation, a specialty pharmaceutical company, and as senior vice president and medical director at SEQUUS Pharmaceuticals, where he oversaw clinical and regulatory functions and was a member of the Executive Committee.
Now serving as a respected and integral figure in cancer therapy research, Schnipper began his journey to success at Hobart and William Smith Colleges, where he earned his B.A. in chemistry. During his time in Geneva, he was inducted into Phi Beta Kappa honors society.
After Schnipper left Geneva, he went on to earn his M.D. from the Georgetown University School of Medicine in Washington, D.C. He trained in medicine at the Long Island Jewish-Hillside Medical Center and completed fellowships in hematology at New York University and in medical oncology at Memorial Sloan-Kettering Cancer Center in New York. He is a member of the American Society of Clinical Oncology, the American Academy of Pharmaceutical Physicians, among many other prestigious medical societies.